2019
DOI: 10.3390/jcm8070998
|View full text |Cite
|
Sign up to set email alerts
|

Liquid Biopsy for the Detection of Resistance Mechanisms in NSCLC: Comparison of Different Blood Biomarkers

Abstract: The use of targeted agents and immunotherapy for the treatment of advanced non-small-cell lung cancer (NSCLC) has made it mandatory to characterize tumor tissue for patient selection. Moreover, the development of agents that are active against specific resistance mechanisms arising during treatment make it equally important to characterize the tumor tissue at progression by performing tissue re-biopsy. Given that tumor tissue is not always available for molecular characterization due to the paucity of diagnost… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
21
0
3

Year Published

2019
2019
2023
2023

Publication Types

Select...
8
1

Relationship

2
7

Authors

Journals

citations
Cited by 31 publications
(25 citation statements)
references
References 182 publications
(215 reference statements)
1
21
0
3
Order By: Relevance
“…One possible explanation is that those tumors rarely metastasize outside the CNS [33], so ctDNA released to the bloodstream is restricted and makes minority allele detection more difficult [34]. Nevertheless, it could be useful when a solid biopsy is not available and for therapy response prediction [35], as has been approved by the FDA in NSCLC patients [9], in which values obtained for EGFR mutations were 100% of specificity and 65.7% of sensitivity [36].…”
Section: Discussionmentioning
confidence: 99%
“…One possible explanation is that those tumors rarely metastasize outside the CNS [33], so ctDNA released to the bloodstream is restricted and makes minority allele detection more difficult [34]. Nevertheless, it could be useful when a solid biopsy is not available and for therapy response prediction [35], as has been approved by the FDA in NSCLC patients [9], in which values obtained for EGFR mutations were 100% of specificity and 65.7% of sensitivity [36].…”
Section: Discussionmentioning
confidence: 99%
“…The utility of ctDNA for assessment of TMBs delivers support for limited or inaccessible tissue samples to improve therapeutic decisions for some cancers (Gandara et al, 2018); however, this is highly dependent on the selection of the gene-targeted panel to evaluate TMBs, and most probably needs to be customized for each cancer type. In addition, the efficiency and precision of the assay using ctDNA to depict TMB is dependent on high coverage of the assay (Gandara et al, 2018;Georgiadis et al, 2019;Pasini and Ulivi, 2019). For breast cancer a NGS panel of mutations associated with 76 target genes, MammaSeq TM , have been recently developed with applicable use of ctDNA.…”
Section: Liquid Biopsies Biomarkersmentioning
confidence: 99%
“…A introdução da biópsia líquida na prática clínica em cancro do pulmão, através do estudo de ADN livre em circulação (cfDNA), traduziu -se na estratégia ideal para monitorização da resposta ao tratamento e deteção atempada do início dos mecanismos de resistência, nomeadamente, na identificação da mutação de resistência T790M. A possibilidade de identificar mecanismos de resistência durante o tratamento pode ajudar a identificar a progressão da doença mais cedo e, deste modo, melhorar a personalização do tratamento destes doentes 36,37 .…”
Section: Importância Do Diagnóstico Molecular Na Prática Clínicaunclassified